

ATHEROGENICS INC  
Form 8-K  
June 01, 2007

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **May 31, 2007**

**ATHEROGENICS, INC.**  
(Exact Name of Registrant as Specified in its Charter)

<b>Georgia</b> (State or other jurisdiction of incorporation)	<b>0-31261</b> (Commission File Number)	<b>58-2108232</b> (I.R.S. Employer Identification Number)
--	---	--

**8995 Westside Parkway**  
**Alpharetta, GA 30004**  
(Address of principal executive offices)

Registrant's telephone number, including area code **(678) 336-2500**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.05 Costs Associated with Exit or Disposal Activities.**

On May 24, 2007, AtheroGenics, Inc. implemented a restructuring plan that reduced its workforce by approximately 50% to 67 employees. The company is providing severance and outplacement support to employees affected by the workforce reduction. The company expects to record a one-time charge of approximately \$1 million in the second quarter of 2006 related to the termination benefits. In addition to the employee termination benefits, we will incur non-cash provisions for asset write downs of approximately \$2 million. These actions were designed to streamline company operations and are the first steps of its new strategic plan, focused on advancing development of its novel drug candidate, AGI-1067.

**Item 8.01. Other Events.**

On May 31, 2007, AtheroGenics, Inc. issued a press release to provide an update on its business plan and announce that it will focus on diabetes as the next step in the clinical development of AGI-1067. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

The following exhibits are filed with this current report on Form 8-K.

<u>Exhibit No.</u>	<u>Description</u>
99.1	- Press Release dated May 31, 2007.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**ATHEROGENICS, INC.**

Date: June 1, 2007

/s/MARK P. COLONNESE

Name: Mark P. Colonnese

Title: Executive Vice President, Commercial  
Operations

and Chief Financial Officer

---

**EXHIBIT INDEX**

Exhibit No. - Description

99.1 - Press Release dated May 31, 2007.

---